VEGF was a key focus in ASCO 2026 targeted therapy presentations, with both bispecific antibodies…
Browsing: biotech analysis
PD-1 remained the core immunotherapy target in ASCO 2026, with hundreds of abstracts featuring PD-1-targeted…
Sorafenib remained the historical benchmark in ASCO 2026 liver cancer presentations, serving as the active…
R-CHOP remained the foundational chemotherapy regimen in ASCO 2026 hematology presentations, serving as the control…
Sacituzumab Govitecan was a benchmark in ASCO 2026 ADC presentations, with updated Phase III data…
Osimertinib was a key reference in ASCO 2026 targeted therapy abstracts, with updated data for…
Pembrolizumab remained a benchmark in ASCO 2026 immunotherapy presentations, with updated Phase III data for…
Tislelizumab was featured in ASCO 2026 abstracts, with updated Phase III data for first-line hepatocellular…
Trastuzumab Deruxtecan continued to be a centerpiece of ASCO 2026 oral presentations, with updated Phase…
Abemaciclib was a key focus in ASCO 2026 abstracts, with Phase III data for dedifferentiated…